Colossal Biosciences, the biotech startup pioneering species de-extinction, is negotiating a major funding round that could value the company at $20–30 billion according to sources—more than triple its last $10.2B valuation in 2025. This reflects surging investor confidence in deep-tech biology ventures.
At a glance: Key facts
- Colossal in discussions for funding at $20–30B valuation
- Began generating revenue last year via government conservation contracts
- Flagship projects: Woolly mammoth, dodo bird and blue antelope revival
- Developing artificial womb with medical applications
- Already spun off three companies: Breaking, Form Bio and Astromech
Funding details and valuation surge
The Austin-based company is actively negotiating with investors, though the lead backer and exact amount remain undisclosed. The potential $20–30B valuation reflects:
- Breakthroughs in CRISPR gene-editing for de-extinction
- $60M+ in government contracts (US/UAE)
- Successful spin-offs including Form Bio ($30M raised)
- Emerging biodiversity credit market potential
Revenue streams and monetization
Colossal has begun monetizing its conservation tech through government partnerships, with future plans for biodiversity credits analogous to carbon offsets—a market projected to exceed $100B by 2030.
- Government contracts: Active conservation partnerships
- Tech licensing: Artificial womb and genetic tools
- Ecological credits: Future revenue pipeline
De-extinction projects and tech
The company's revival pipeline includes woolly mammoths, dodos and blue antelope, plus genetic therapies to save Tasmanian devils. Its artificial womb—potentially ready by 2027—could transform reproductive medicine.
Technology milestones
| Technology | Status | Applications |
|---|---|---|
| Artificial womb | Testing (2027 expected) | Reproductive medicine, species conservation |
| Tasmanian devil gene therapy | Clinical trials | Treating facial tumor disease |
| Mammoth hybridization | Preclinical research | Arctic ecosystem restoration |
Spin-off companies
- Breaking: Plastic recycling tech
- Form Bio: Computational biology platform ($30M raised)
- Astromech: AI for life sciences ($2B valuation)
Challenges and criticism
- Ethics: Scientific debate over de-extinction merits
- Technical hurdles: Significant biological barriers remain
- Regulation: GMO species introduction restrictions
Questions & answers
What species is Colossal trying to revive?
Woolly mammoths, dodos and blue antelope—projects aimed at ecosystem restoration. Mammoth reintroduction could slow permafrost thaw.
How does Colossal make money?
Current $40-60M annual revenue comes from government conservation tech sales, with future biodiversity credits planned.
Who's investing in Colossal?
Current round backers undisclosed. Past investors include UAE Sovereign Wealth Fund and Breakthrough Energy Ventures.
What tech is Colossal developing?
Artificial wombs, gene-editing tools and computational biology platforms with medical/ecological applications.
What's the de-extinction market potential?
Analysts project $500B by 2040 driven by environmental initiatives and biotech advancements.